RxDoctor Payments Data

Rishi Raj, MD

Critical Care Medicine · Lubbock, TXNPI 1730296575

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 98.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $3,905 and has fallen 89.7% since, to $402 in 2025.

$8,932in general payments, 2019–2025

Across 15 payments — averaging $595.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$9K
  • Intuitive Surgical$153
  • Melinta Therapeutics, LLC$14
$1,855,331in research payments, 2019–2025

Across 188 payments — averaging $9868.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$618K
  • Boehringer Ingelheim$603K
  • E.r. Squibb & Sons, L.L.C.$431K
  • Roche Products Limited$191K
  • Bristol Myers Squibb$13K

What the payments were for

  • Consulting fees$3,90044%
  • Speaking & faculty fees$4,45850%
  • Food & beverage$5696%
  • Education$50%

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,932 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$57,331
Medicare patients
141
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate123$1,385,357
Pirfenidone37$24,902
MethotrexateMethotrexate Sodium13$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$8,765$1,385,357123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →